BGT226 is primarily used in cancer research as a potent inhibitor of the PI3K/mTOR signaling pathway, which plays a key role in cell growth, proliferation, and survival. It shows potential in targeting tumors with mutations in the PI3K pathway, commonly found in cancers such as breast, lung, and prostate. Due to its dual inhibitory action on both PI3K and mTOR, BGT226 can help overcome resistance seen with single-pathway inhibitors. It has been studied in preclinical models to evaluate its antitumor efficacy and pharmacokinetic properties, supporting its development as a targeted therapy in oncology. Research use only; not approved for clinical use in humans.